J L Mega1, N O Stitziel2, S Kathiresan3, M S Sabatine1, J G Smith4,3, D I Chasman5, M Caulfield6, J J Devlin7, F Nordio1, C Hyde8, C P Cannon1, F Sacks9, N Poulter10, P Sever10, P M Ridker11, E Braunwald1, O Melander12. 1. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 2. Cardiovascular Division, Department of Medicine and Division of Statistical Genomics, Washington University School of Medicine, Saint Louis, MO. 3. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT; Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 4. Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden. 5. Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 6. William Harvey Research Institute, Queen Mary University of London and Barts NIHR CV Biomedical Research Institute, London, United Kingdom. 7. Quest Diagnostics, Alameda, CA. 8. Pfizer Research Laboratory, Groton, CT. 9. Department of Nutrition, Harvard School of Public Health and Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA. 10. International Centre for Circulatory Health, National Heart & Lung Institute, Imperial College London, United Kingdom. 11. Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 12. Department of Clinical Sciences, Faculty of Medicine, Lund University and Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden.
Abstract
BACKGROUND: Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy. METHODS: A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis. FINDINGS: When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was shown. Compared with the low genetic risk category, the multivariable-adjusted hazard ratio for coronary heart disease for the intermediate genetic risk category was 1·34 (95% CI 1·22-1·47, p<0·0001) and that for the high genetic risk category was 1·72 (1·55-1·92, p<0·0001). In terms of the benefit of statin therapy in the four randomised trials, we noted a significant gradient (p=0·0277) of increasing relative risk reductions across the low (13%), intermediate (29%), and high (48%) genetic risk categories. Similarly, we noted greater absolute risk reductions in those individuals in higher genetic risk categories (p=0·0101), resulting in a roughly threefold decrease in the number needed to treat to prevent one coronary heart disease event in the primary prevention trials. Specifically, in the primary prevention trials, the number needed to treat to prevent one such event in 10 years was 66 in people at low genetic risk, 42 in those at intermediate genetic risk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT. INTERPRETATION: A genetic risk score identified individuals at increased risk for both incident and recurrent coronary heart disease events. People with the highest burden of genetic risk derived the largest relative and absolute clinical benefit from statin therapy. FUNDING: National Institutes of Health.
BACKGROUND: Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy. METHODS: A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis. FINDINGS: When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was shown. Compared with the low genetic risk category, the multivariable-adjusted hazard ratio for coronary heart disease for the intermediate genetic risk category was 1·34 (95% CI 1·22-1·47, p<0·0001) and that for the high genetic risk category was 1·72 (1·55-1·92, p<0·0001). In terms of the benefit of statin therapy in the four randomised trials, we noted a significant gradient (p=0·0277) of increasing relative risk reductions across the low (13%), intermediate (29%), and high (48%) genetic risk categories. Similarly, we noted greater absolute risk reductions in those individuals in higher genetic risk categories (p=0·0101), resulting in a roughly threefold decrease in the number needed to treat to prevent one coronary heart disease event in the primary prevention trials. Specifically, in the primary prevention trials, the number needed to treat to prevent one such event in 10 years was 66 in people at low genetic risk, 42 in those at intermediate genetic risk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT. INTERPRETATION: A genetic risk score identified individuals at increased risk for both incident and recurrent coronary heart disease events. People with the highest burden of genetic risk derived the largest relative and absolute clinical benefit from statin therapy. FUNDING: National Institutes of Health.
Authors: Sekar Kathiresan; Olle Melander; Dragi Anevski; Candace Guiducci; Noël P Burtt; Charlotta Roos; Joel N Hirschhorn; Göran Berglund; Bo Hedblad; Leif Groop; David M Altshuler; Christopher Newton-Cheh; Marju Orho-Melander Journal: N Engl J Med Date: 2008-03-20 Impact factor: 91.245
Authors: Vinicius Tragante; Pieter A F M Doevendans; Hendrik M Nathoe; Yolanda van der Graaf; Wilko Spiering; Ale Algra; Gert Jan de Borst; Paul I W de Bakker; Folkert W Asselbergs Journal: Eur Heart J Date: 2013-07-04 Impact factor: 29.983
Authors: Olga A Iakoubova; Carmen H Tong; Anand P Chokkalingam; Charles M Rowland; Todd G Kirchgessner; Judy Z Louie; Lynn M Ploughman; Marc S Sabatine; Hannia Campos; Joseph J Catanese; Diane U Leong; Bradford A Young; David Lew; Zenta Tsuchihashi; May M Luke; Christopher J Packard; Kim E Zerba; Peter M Shaw; James Shepherd; James J Devlin; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2006-09-28 Impact factor: 8.311
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: Anke-Hilse Maitland-van der Zee; Amy Lynch; Eric Boerwinkle; Donna K Arnett; Barry R Davis; Catherine Leiendecker-Foster; Charles E Ford; John H Eckfeldt Journal: Pharmacogenet Genomics Date: 2008-08 Impact factor: 2.089
Authors: Marc S Sabatine; Lynn Ploughman; Katy L Simonsen; Olga A Iakoubova; Todd G Kirchgessner; Koustubh Ranade; Zenta Tsuchihashi; Kim E Zerba; Diane U Long; Carmen H Tong; Christopher J Packard; Marc A Pfeffer; James J Devlin; James Shepherd; Hannia Campos; Frank M Sacks; Eugene Braunwald Journal: Arterioscler Thromb Vasc Biol Date: 2008-01-03 Impact factor: 8.311
Authors: Olga A Iakoubova; Marc S Sabatine; Charles M Rowland; Carmen H Tong; Joseph J Catanese; Koustubh Ranade; Katy L Simonsen; Todd G Kirchgessner; Christopher P Cannon; James J Devlin; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2008-01-29 Impact factor: 24.094
Authors: Riyaz S Patel; Folkert W Asselbergs; Arshed A Quyyumi; Tom M Palmer; Chris I Finan; Vinicius Tragante; John Deanfield; Harry Hemingway; Aroon D Hingorani; Michael V Holmes Journal: J Am Coll Cardiol Date: 2014-03-07 Impact factor: 24.094
Authors: Wei Wang; Yang Tang; Ying Wang; Liana Tascau; Joanna Balcerek; Wei Tong; Ross L Levine; Carrie Welch; Alan R Tall; Nan Wang Journal: Circ Res Date: 2016-07-18 Impact factor: 17.367
Authors: Catherine Hajek; Xiuqing Guo; Jie Yao; Yang Hai; W Craig Johnson; Alexis C Frazier-Wood; Wendy S Post; Bruce M Psaty; Kent D Taylor; Jerome I Rotter Journal: Circ Genom Precis Med Date: 2018-10